CIENA (CIEN) Form 144 Filing Reports 350-Share Proposed Sale
Rhea-AI Filing Summary
CIENA Corp (CIEN) Form 144 summary: An individual (Brodie Gage) filed a notice to sell 350 restricted shares of CIENA common stock, with an aggregate market value of $46,200, scheduled approximately for 09/15/2025 on the NYSE. The shares were acquired from the issuer as restricted stock on 06/20/2024. The filing reports three recent sales by the same person in the past three months: 350 shares on 08/15/2025 for $31,829; 350 shares on 07/15/2025 for $28,899.50; and 350 shares on 06/16/2025 for $25,410, totaling 1,050 shares recently sold. Outstanding shares are listed as 141,055,908, making the current proposed sale a very small fraction of the company’s outstanding common stock.
Positive
- Sale size is immaterial relative to 141,055,908 outstanding shares, suggesting limited market impact
- Full disclosure provided including acquisition date, nature of acquisition (restricted stock), broker, and recent sales
Negative
- None.
Insights
TL;DR: Routine insider sale of a small restricted position; not material to CIEN’s market capitalization.
The filing documents a planned sale of 350 restricted shares acquired from the issuer on 06/20/2024. With 141,055,908 shares outstanding, the proposed sale represents an immaterial fraction of the float. The seller has executed three recent small sales totaling 1,050 shares and realized modest gross proceeds. From a capital-markets perspective, these transactions appear consistent with personal liquidity or diversification rather than a company-specific signal, given the small absolute and relative sizes.
TL;DR: Disclosure complies with Rule 144 requirements; signer affirms no undisclosed material information.
The Form 144 provides required details: acquisition date, nature (restricted stock), broker name, planned sale date, and recent sales history. The filer signs the standard attestation regarding material nonpublic information and trading-plan implications. There is no indication in the filing of reliance on a 10b5-1 plan or other corporate governance flags. This is a routine disclosure consistent with regulatory expectations.